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Background: Advanced hepatocellular carcinoma (HCC) not
amenable to local therapies has limited chances of cure and has
a poor prognosis. Sorafenib is a multikinase inhibitor with proven
activity in advanced HCC. Octreotide is already used in this set-
ting with conflicting but usually interesting results.
Methods: An original schedule with sorafenib and long-acting
octreotide is currently tested in advanced HCC enrolled from dif-
ferent institutions. Sorafenib is administered at a dosage of
400 mg/daily for 28 d with a following week of rest. Ten days after
starting sorafenib, long acting octreotide is administered at a dose
of 40 mg with monthly scheduled administrations. Objectives of
this study are the evaluation of activity and potential toxicity of
the treatment. Tumor response is assessed bimontly.
Results:At the date of 28 April 2008, 57 patientswere considered
for study entry and 42 were enrolled (sex: 33M/9F; age range: 57–80
years; HCV: 26 patients, HBV: 10 patients, HCV + HBV: 1 patient;
unknown etiology: 5 patients; childA/B: 31/11). Patients naı¨ve from
other therapieswere 19, whilst all the otherswere previously trea-
tedwith local and/or systemic treatments. Threepatientswere not
evaluable because of premature treatment stopping caused by
diarrhoea grade 3. Twenty-four patients were evaluated until
now. Among 12 patients evaluable after 2 months of therapy, we
registered 1 minimal response, 3 stable disease and 8 disease pro-
gression. Among 8 patients evaluable after 4 months, we reported
5 stable disease and 3 disease progression. Among 4 patients
evaluable after 6 months, we reported 1 minimal response and 3
stable disease. Treatment was generally well tolerated apart from
haemorrhoidal bleeding (2 patients), skin toxicity grade 2 and
grade 3 in 2 patients, respectively, hypertension in 3 patients.
Conclusions: The association of sorafenib and long acting octre-
otide appears feasible in advanced hepatocellular carcinomas not
susceptible of local therapies. Longer follow-up of this study is
needed to evaluate clinical activity of this schedule.
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Background: FOLFOX regimen represents a standard first
line therapy for ACRC. Recent studies observed that tri-weekly
XELOX administration is characterised by effectiveness and toler-
ance similar to FOLFOX 4 infusional schedule. This phase II mul-
ticenter study of the Gruppo Oncologcio dell’Italia Meridionale
(GOIM) started to evaluate the activity and the toxicity of bi-
weekly administration of capecitabine + oxaliplatin in ACRC
patients.
Materials and methods: Thirty-two advanced colorectal cancer
pts with measurable disease, ECOG PS 6 2, age 18–75 years (yrs)
were enrolled. The schedule of treatment was as follows: oxalipl-
atin at 100 mg/mq i.v. on day 1 and capecitabine at 2000 mg/mq
p.o. in a two daily administration from days 1 to 7, every 2 weeks.
The recist and NCI criteria were employed to determine the activ-
ity and the toxicity of this combination, respectively.
Results: At present, 32 patients have been enrolled and up to
now 29 of them are evaluable for activity and toxicity. The main
characteristics were: sex (M/F) 23/9, median age 70 yrs (range
54–75), median PS 0, main sites of disease: liver 26 (81%),
lymph-nodes 9 (28%) and lung 4 (12%). One CR (3%) and 12 PR
(42%), 8 SD (27%) and 8 PD (27%) were observed. The main toxicity
rate (G1–2 versus G3–4) were: thrombocytopenia 44/6, anaemia
41/0, nausea/vomiting 28/0, diarrhoea 22/0, neurotoxicity 50/0
and asthenia 16/3.
Conclusions: These preliminary data show that the bi-weekly
administration of capecitabine + oxaliplatin is active and well tol-
erated by ACRC patients. This study is still ongoing.
doi:10.1016/j.ejcsup.2008.06.040
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Background: Irinotecan (Cpt-11) plus fluorouracil (Fu) modu-
lated by folinic acid (Fa) (folfiri regimen) is one of the standard
first-line treatment in advanced colorectal cancer (ACC). The oral
fluoropyrimidine xeloda (Xel) is equivalent in terms of efficacy
and demonstrated a better safety profile than bolus Fu–Fa.
Besides Xel can replace Fu continuous infusion. Also the combi-
nation of Cpt-11 plus Xel (xeliri regimen) demonstrated to be
active as a first-line treatment in ACC patients. So the GOIM
started a randomised multicenter phase II trial aiming to com-
pare the activity and safety of folfiri and xeliri in this setting.
Methods: Untreated patients with histologically confirmed
diagnosis of colorectal cancer entered into the trial if they satis-
fied the following inclusion criteria: presence of measurable dis-
ease (recist criteria), age > 18 years, performance status < 2 (Ecog
scale), adequate bone marrow reserve and renal and hepatic
function, informed written consent. The enrolled patients were
randomised 1:2 to receive arm A: Cpt-11 at 180 mg/m2 on day 1,
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